No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Shilpa Medicare Limited, including its associated entities, specializes in the production and global distribution of active pharmaceutical ingredients (APIs), chemical intermediates, and finished drug formulations, serving markets across India, the United States, Europe, and internationally. Its extensive product catalog features prominent oncology APIs such as capecitabine, gemcitabine hydrochloride, pemetrexed, axitinib, erlotinib hydrochloride, and irinotecan hydrochloride, alongside non-oncology APIs like ambroxol, tranexamic acid, and ursodeoxycholic acid. The company also develops innovative drug delivery systems, biotechnological products (including peptides), and specialty chemicals. Furthermore, Shilpa Medicare offers comprehensive contract manufacturing services for a diverse range of dosage forms, including tablets, capsules, liquid, lyophilized, and sterile dry powder injectables. Complementing its core pharmaceutical activities, the company also diversifies into wind energy generation. Established in 1987, Shilpa Medicare Limited maintains its corporate base in Raichur, India.
www.vbshilpa.comNo one on the platform currently holds SHILPAMED.BO.
No tracked institution reports a position in SHILPAMED.BO as of their last filing.
No one on the platform has traded SHILPAMED.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 8.1% | — | — | — | ||
| Rev. Growth % | 19.6% | 11.3% | ||||
| Profit Margin % | 15.8% | 5.4% | 10.5% | |||
| Free Cash Flow Margin % | -4.9% | -8.4% | -14.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $19.0B | +25.8% | $15.18 | $13.38–$16.62 | — | 4 |
| 2028 | $23.2B | +22.2% | $21.06 | $18.32–$23.72 | — | 4 |
| 2029 | $29.6B | +27.8% | $29.82 | $25.44–$33.25 | — | 1 |
| 2030 | $26.9B | -9.1% | $22.80 | $19.45–$25.42 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 6 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $4.00 | $5.18 | +29.5% |
| 2026-05-22 | $3.30 | $5.51 | +67.0% |
| 2026-02-06 | $2.80 | $2.30 | -17.9% |
| 2025-11-13 | $4.40 | $2.25 | -48.9% |
| 2025-08-13 | $1.85 | $2.40 | +29.7% |
| 2025-05-26 | $2.95 | $1.70 | -42.4% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| SHILPAMED.BOShilpa Medicare Limited | $911.85 | -5.31% | $89.2B | — |
| GUFICBIO.BOGufic Biosciences Limited | $425.00 | -1.16% | $42.6B | — |
| GUFICBIO.NSGufic Biosciences Limited | $425.10 | +0.00% | $42.6B | — |
| HIKAL.BOHikal Limited | $212.35 | -6.47% | $26.1B | — |
| HIKAL.NSHikal Limited |
| $212.22 |
| -5.66% |
| $26.2B |
| — |
| IOLCP.NSIOL Chemicals and Pharmaceuticals Limited | $179.52 | -7.61% | $52.7B | — |
| ORCHPHARMA.NSOrchid Pharma Limited | $987.00 | -1.60% | $50.1B | — |
Source: Financial Modeling Prep · peers by sector/industry